Maike Pharmaceutical-B (02335): The Phase II clinical trial of MT200605 for the treatment of acute ischemic stroke (AIS) has achieved its primary endpoint.

Zhitong Finance APP news, MaiKe Pharmaceutical-B (02335) announced that the Phase II clinical trial of its self-developed candidate drug MT200605 for the treatment of AIS (the clinical trial) has achieved topline data. The data shows that the clinical trial has met its primary endpoint, with results that are statistically significant and clinically meaningful.